This research matters for patients with metastatic colorectal cancer that has specific genetic markers known as dMMR or MSI-H. These markers indicate the tumor has defects in its ability to repair DNA damage. For these specific patients, standard chemotherapy has historically shown limited effectiveness. This new analysis brings together data from multiple clinical trials to see if newer immunotherapy drugs work better. The study combined results from 1460 patients to provide a clearer picture than any single trial could offer alone.
The researchers looked at two main types of immunotherapy treatments. The first was PD-1 inhibitor monotherapy, which uses drugs like nivolumab or pembrolizumab alone. The second was dual immunotherapy, which combines nivolumab with ipilimumab. They compared these options against standard chemotherapy. The primary goal was to see how many patients experienced a tumor response, known as the objective response rate. Secondary goals included looking at how long patients lived without the cancer growing and how well they tolerated the treatments.
The results showed a clear benefit for PD-1 inhibitor monotherapy compared to chemotherapy. Patients receiving the immunotherapy alone had a significantly higher chance of their tumors shrinking. The statistical analysis showed an odds ratio of 1.52, meaning the likelihood of a response was much higher. When looking at dual immunotherapy versus monotherapy, the response rate was even higher with the combination approach. However, this came with a trade-off. Patients on the dual therapy had a significantly higher risk of severe side effects compared to those on monotherapy alone.
Safety was a major part of the analysis. The data showed that patients on PD-1 inhibitor monotherapy had a much lower risk of severe side effects compared to chemotherapy. The odds of experiencing grade 3 or higher adverse events were significantly lower. In contrast, adding ipilimumab to nivolumab increased the risk of these severe side effects. The study also looked at overall survival across four different trials. Unfortunately, the analysis did not find a statistically significant improvement in overall survival time. Confidence intervals were wide, and statistical significance was not consistently observed across all the trials included.
This study helps doctors make better decisions for patients with dMMR or MSI-H metastatic colorectal cancer. It suggests that PD-1 inhibitors are a strong option that works better than chemotherapy for this specific group. However, the lack of consistent overall survival benefit and the wide confidence intervals mean patients should not expect a guaranteed cure. The choice between monotherapy and dual therapy depends on weighing the higher response rates against the increased risk of severe side effects. Patients should discuss these risks and benefits with their oncology team to find the best personalized plan for their situation.